Neuroscience

Linus Health Leader to Join ‘Brainiacs’ Panel at HLTH 2024 to Discuss Advancements in Cognitive Impairment Screening

Company also a finalist for Digital Health Awards to be announced on opening night BOSTON, Oct. 17, 2024 /PRNewswire/ --…

1 year ago

Sarah Sheikh Joins Cerevance’s Board of Directors

BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment…

1 year ago

Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints

– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients…

1 year ago

Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth

MANCHESTER, England, Oct. 15, 2024 /PRNewswire/ -- Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment…

1 year ago

Neurophet-AriBio to develop ‘Next-Gen Platform for Alzheimer’s diagnosis’

- Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global Phase 3 clinical trial for Alzheimer's disease…

1 year ago

Perceiv AI Welcomes Simona Skerjanec to Board of Directors

Thought Leader in Brain Health Joins Richard Stark and Company Co-Founders to Accelerate Innovation in Precision MedicineMONTREAL, QC / ACCESSWIRE…

1 year ago

Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or…

1 year ago

NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression

Data selected for oral presentation reinforce previous findings on safety and efficacyMALVERN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Neuronetics,…

1 year ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…

1 year ago

Five to Flow® Unveils Next-Generation Wellness Wave® Diagnostic for Improved Workplace Wellness and Productivity, Supporting World Mental Health Day’s Workplace Well-Being Focus

The enhanced employee sentiment tool equips employees and leaders to address stress, burnout, disengagement, and turnover for lasting growth and…

1 year ago